OBJECTIVE:To investigate the therapeutic effects of Chinese medicine Weifuchun(WFC,胃复春)on gastric fundic gland polyps(FGPs).METHODS:FGPs organoids were constructed with patients-derived samples.The morphology and s...OBJECTIVE:To investigate the therapeutic effects of Chinese medicine Weifuchun(WFC,胃复春)on gastric fundic gland polyps(FGPs).METHODS:FGPs organoids were constructed with patients-derived samples.The morphology and size of FGPs organoids were detected using bright-field imaging.Effective components and corresponding potential targets of WFC were screened using multiple opensource databases and research on Traditional Chinese Medicine or compound formulas.Core genes were identified through protein-protein interaction networks.Kyoto Encyclopedia of Genes and Genomes(KEGG)and Gene Ontology(GO)enrichment analyses of the core genes were conducted.The interactions between main components and core targets were analyzed through the Ferr Db database.The expressions of core targets were detected by quantitative real-time polymerase chain reaction(q RT-PCR).RESULTS:After WFC treatment,the number and size of FGPs organoids were significantly reduced.Twenty nine active drug components and 162 candidate targets of WFC for treating FGPs were identified,including 37 targets related to ferroptosis.Quercetin,Glaucocalyxin B,Melissoidesin U,Melissoidesin O,Hesperetin,Glaucocalyxin A,Angustifolin,Melissoidesin M,Di-n-octyl phthalate,and beta-sitosterol were identified as the main active compounds.SRC proto-oncogene,non-receptor tyrosine kinase,signal transducer and activator of transcription 3,phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha,phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta,phosphoinositide-3-kinase regulatory subunit 1,and AKT serine/threonine kinase 1 were identified as the primary targets.KEGG pathways related to carcinogenesis,cell proliferation and metabolism,and oxidative stress.WFC promoted FGPs organoids'death and could be reversed by ferroptosis inhibitor of Erastin.The q RT-PCR results showed that WFC treatment could regulate the m RNA expression levels of solute carrier family 7 member 11,acyl-Co A synthetase long chain family member 4,and arachidonate 15-lipoxygenase,type B.CONCLUSION:WFC may exert its therapeutic effects by inducing ferroptosis in FGPs cells.展开更多
目的基于临床病例的回顾性研究,初步探讨胃下垂患者的临床特征、疾病预测因素、临床分型、证型分布特点及中西医治疗规律。方法收集2019年9月—2021年8月在东直门医院脾胃病科通过造影剂辅助胃显影进行胃下垂筛查的序列患者资料。采集...目的基于临床病例的回顾性研究,初步探讨胃下垂患者的临床特征、疾病预测因素、临床分型、证型分布特点及中西医治疗规律。方法收集2019年9月—2021年8月在东直门医院脾胃病科通过造影剂辅助胃显影进行胃下垂筛查的序列患者资料。采集关键信息,建立数据库。围绕临床特征、疾病预测因素、临床分型、证候分布特点等4个项目进行数据分析。结果检索到患者112例,纳入103例,其中胃下垂患者69例,无胃下垂患者34例。(1)临床特征方面。与无胃下垂组相比,胃下垂组患者体质量指数(body mass index,BMI)更低,病程及确诊时间长。(2)疾病预测因素方面。单因素分析及Logistics回归分析证实BMI与疾病发生密切相关。该指标的受试者工作曲线(ROC曲线)下面积为0.798。其中BMI低于18.04 kg/m2是最佳临床诊断切点,预测敏感度87%,特异度76.5%;BMI低于19 kg/m2是最佳筛查启动点,其敏感度为95%,特异度为38%。(3)临床分型研究方面。经典胃下垂组与临界胃下垂组症状相似,但后者平均年龄更轻,BMI更高,胃下垂程度更轻。(4)中医证型分布研究方面。脾胃湿热证多见,气虚及气滞是最常见证素。结论BMI可作为胃下垂筛查、诊断及疗效评估的核心指标;临界胃下垂应视为该病的早期阶段和最重要干预阶段;脾虚胃滞或为胃下垂的核心病机;胃下垂应围绕营养管理、症状控制及精神疏导进行综合管理。展开更多
基金the National Administration of Traditional Chinese Medicine Letter([2022]-1)Dongzhimen Hospital Horizontal Project:Exploring the Effects of Weifuchun on Key Mechanisms of Different Types of Gastric Polyps based on Human Organoid Culture Technology(No.HX-DZM-202239)the Qihuang Talent Program for Renowned Physician Cultivation at Beijing University of Chinese Medicine(No.Y2023A06)。
文摘OBJECTIVE:To investigate the therapeutic effects of Chinese medicine Weifuchun(WFC,胃复春)on gastric fundic gland polyps(FGPs).METHODS:FGPs organoids were constructed with patients-derived samples.The morphology and size of FGPs organoids were detected using bright-field imaging.Effective components and corresponding potential targets of WFC were screened using multiple opensource databases and research on Traditional Chinese Medicine or compound formulas.Core genes were identified through protein-protein interaction networks.Kyoto Encyclopedia of Genes and Genomes(KEGG)and Gene Ontology(GO)enrichment analyses of the core genes were conducted.The interactions between main components and core targets were analyzed through the Ferr Db database.The expressions of core targets were detected by quantitative real-time polymerase chain reaction(q RT-PCR).RESULTS:After WFC treatment,the number and size of FGPs organoids were significantly reduced.Twenty nine active drug components and 162 candidate targets of WFC for treating FGPs were identified,including 37 targets related to ferroptosis.Quercetin,Glaucocalyxin B,Melissoidesin U,Melissoidesin O,Hesperetin,Glaucocalyxin A,Angustifolin,Melissoidesin M,Di-n-octyl phthalate,and beta-sitosterol were identified as the main active compounds.SRC proto-oncogene,non-receptor tyrosine kinase,signal transducer and activator of transcription 3,phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha,phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta,phosphoinositide-3-kinase regulatory subunit 1,and AKT serine/threonine kinase 1 were identified as the primary targets.KEGG pathways related to carcinogenesis,cell proliferation and metabolism,and oxidative stress.WFC promoted FGPs organoids'death and could be reversed by ferroptosis inhibitor of Erastin.The q RT-PCR results showed that WFC treatment could regulate the m RNA expression levels of solute carrier family 7 member 11,acyl-Co A synthetase long chain family member 4,and arachidonate 15-lipoxygenase,type B.CONCLUSION:WFC may exert its therapeutic effects by inducing ferroptosis in FGPs cells.
文摘目的基于临床病例的回顾性研究,初步探讨胃下垂患者的临床特征、疾病预测因素、临床分型、证型分布特点及中西医治疗规律。方法收集2019年9月—2021年8月在东直门医院脾胃病科通过造影剂辅助胃显影进行胃下垂筛查的序列患者资料。采集关键信息,建立数据库。围绕临床特征、疾病预测因素、临床分型、证候分布特点等4个项目进行数据分析。结果检索到患者112例,纳入103例,其中胃下垂患者69例,无胃下垂患者34例。(1)临床特征方面。与无胃下垂组相比,胃下垂组患者体质量指数(body mass index,BMI)更低,病程及确诊时间长。(2)疾病预测因素方面。单因素分析及Logistics回归分析证实BMI与疾病发生密切相关。该指标的受试者工作曲线(ROC曲线)下面积为0.798。其中BMI低于18.04 kg/m2是最佳临床诊断切点,预测敏感度87%,特异度76.5%;BMI低于19 kg/m2是最佳筛查启动点,其敏感度为95%,特异度为38%。(3)临床分型研究方面。经典胃下垂组与临界胃下垂组症状相似,但后者平均年龄更轻,BMI更高,胃下垂程度更轻。(4)中医证型分布研究方面。脾胃湿热证多见,气虚及气滞是最常见证素。结论BMI可作为胃下垂筛查、诊断及疗效评估的核心指标;临界胃下垂应视为该病的早期阶段和最重要干预阶段;脾虚胃滞或为胃下垂的核心病机;胃下垂应围绕营养管理、症状控制及精神疏导进行综合管理。
